BrainStorm director granted 150K stock options

BrainStorm Cell Therapeutics director Anthony J. Polverino received a grant of stock options to acquire 150,000 shares of common stock at an exercise price of $0.70 per share.

Rhea-AI Filing Summary

BrainStorm Cell Therapeutics director Anthony J. Polverino received a grant of stock options to acquire 150,000 shares of common stock at an exercise price of $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and are a form of equity compensation.

The options vest in two equal parts: 50% vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant, provided he remains employed through each vesting date. All 150,000 options are scheduled to expire on February 26, 2036, giving a long-dated incentive tied to the company’s share performance.

Insider Trade Summary

Grant/Award: 150,000 shares

Grant/Award 1 txn

Insider Polverino Anthony J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	150,000	$0.70	$105K

Holdings After Transaction: Stock Option (Right to Buy) — 150,000 contracts (Direct)

Footnotes (2)

1. F1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
2. F2. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

Key Figures

Options granted: 150,000 options Exercise price: $0.70 per share Underlying shares: 150,000 shares +2 more

5 metrics

Options granted 150,000 options Stock Option (Right to Buy) grant to director

Exercise price $0.70 per share Conversion or exercise price of options

Underlying shares 150,000 shares Common stock underlying granted options

Expiration date February 26, 2036 Option expiration

Post-grant derivative holdings 150,000 options Total derivative shares following transaction

Key Terms

Stock Option (Right to Buy), 2014 Stock Incentive Plan, vest, exercise price, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2014 Stock Incentive Plan financial

"options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan"

vest financial

"The Stock Options shall vest as to (i) 50% of the award on the date of grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: 0.7000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-02-26T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BRAINSTORM CELL THERAPEUTICS (BCLI) director Anthony J. Polverino receive in this Form 4?

Anthony J. Polverino received stock options to acquire 150,000 shares of common stock at $0.70 per share. The options were granted as equity compensation under BrainStorm’s 2014 Stock Incentive Plan, aligning part of his pay with future stock performance.

What is the exercise price of the new BCLI stock options granted to Anthony J. Polverino?

The stock options have an exercise price of $0.70 per share. This means Polverino can buy up to 150,000 BrainStorm Cell Therapeutics common shares at $0.70, regardless of the market price, once the options are vested and until they expire.

How do the BCLI options granted to Anthony J. Polverino vest over time?

The options vest in two stages: 50% of the award vests on the grant date, and the remaining 50% vests on the six-month anniversary. Vesting is conditioned on Polverino remaining employed by BrainStorm Cell Therapeutics through each respective vesting date, following the plan’s terms.

When do Anthony J. Polverino’s BCLI stock options expire?

The options are scheduled to expire on February 26, 2036. After that date, any unexercised options become worthless. This long expiration period gives Polverino many years to decide whether to exercise, depending on BrainStorm’s share price and his own circumstances.

Are the BCLI stock options reported in this Form 4 part of a compensation plan?

Yes. The footnotes state the options were granted under BrainStorm Cell Therapeutics’ 2014 Stock Incentive Plan. Such plans are typical equity compensation programs used to reward directors and executives with long-term incentives linked to company performance and shareholder value.

Does this BCLI Form 4 show open-market buying or selling of shares by Anthony J. Polverino?

No. The filing reports a grant of stock options coded as a grant or award acquisition, not an open-market trade. It reflects compensation in derivative form, giving rights to buy shares later, rather than an immediate purchase or sale in the public market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 06:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Polverino Anthony J.

(Last) (First) (Middle)

C/O BRAINSTORM CELL THERAPEUTICS INC.

1325 AVENUE OF THE AMERICAS 28TH FLOOR

(Street)

NEW YORK NEW YORK 10019

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRAINSTORM CELL THERAPEUTICS INC. [ BCLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$0.7	02/26/2026		A		150,000		(2)	02/26/2036	Common Stock	150,000	$0.7(1)	150,000	D

Explanation of Responses:

1. Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.

2. The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.

	/s/ Anthony J. Polverino	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)